Cited in boardrooms, legal proceedings & government briefings since 2017
Medical cannabis is limited in France and adult-use is illegal. Below: a free market overview, with the full sizing, regulation and trade data available from PP.
Medical cannabis sales and registered patients in France, 2025 actuals and the 2027 forecast. Forecasts to 2030 are in the France data pack.
Medical sales, EUR
| Metric | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| Medical sales | — | — | €3.3m | |||
| Patients | — | — | 5,454 |
Forecasts to 2030 — sales, patients and the full France series — are in the France data pack, or scoped to your question in a bespoke brief.
See the data pack Request a briefSource: Prohibition Partners — Global Medical Cannabis Market Review (2026, updated April 2026) & The European Cannabis Report (2025)
How France’s framework got here, and what moves next.
Medical cannabis trial begins
A small-scale trial programme starts, and is then repeatedly extended while a permanent framework is debated.
European Commission notified
France notifies the EC of its intention to legalise medical cannabis authorisation and production, starting the TRIS procedure.
Permanent system expected
Three implementing decrees await EU sign-off; the HAS will rule on reimbursement, and the ~1,600 trial patients transition to the new system.
Commercial market activation forecast
PP forecasts France activating commercially in 2027, reaching an estimated €17.9 million by 2029.
From International Cannabis Weekly, our free global briefing.
Newsweed · №467 · 18 Sept 2026 · Regulation
Business of Cannabis · №466 · 11 Sept 2026 · Regulation
Newsweed · №465 · 4 Sept 2026 · Regulation
Hanf Magazin · №462 · 14 Aug 2026 · Regulation
Cannabis Industrie · №460 · 31 Jul 2026 · Medical
Cannabis Health · №457 · 10 Jul 2026 · Medical
After several years of continually extending a small-scale medical cannabis trial programme, with seemingly little appetite from French regulators for engaging with medical cannabis more meaningfully, the government has now created a legislative framework to establish permanent medical cannabis treatment within the healthcare system, as well as a domestic industry.
The new system is expected to be in place by at least April 2026, as the Minister of Health stated that the 1,600 patients still being treated as part of the ongoing trial will continue to be able to access their medicine until then. The assumption is that they could then access their medicine through the new system.
The new laws will come into effect with the signing of three decrees detailing the legislation. These decrees have been submitted to the European Union (EU), and once they have been signed off at the EU level, they will then be signed at the ministerial level in France. Both of these steps are expected to be formalities, so the path to implementation is clear.
Granulated flower products may be included in the new system, a shift from the latter stages of the trial where only extract products were permitted.
In the full France market data
Sizing, forecasts, pricing, trade flows and licensed operators — verified by PP’s analysts. Available as a data pack.
